News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Gebro Pharma Signs A Licensing Agreement With Recordati S.p.A For The Commercialization Of Kentera® In Spain



2/27/2014 8:48:10 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

27 February 2014- The Austrian company, Gebro Pharma and the Italian company Recordati, had recently signed an exclusive agreement for distribution, promotion and commercialization of Kentera in Spain.

Kentera® is indicated for the symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in adult patients with unstable bladder. The urinary incontinence market in Spain has a turnover of 87M Euro.

Kentera® 3.9mg/24 hours is a transdermal patch of oxybutynin and is applied twice weekly. The key advantage of Kentera® over other anticholinergics is its side-effect profile. As a patch, Kentera® avoids pre-systemic gastrointestinal and first-pass metabolism which occur with oral therapies. This metabolism is associated with higher plasma levels of the active metabolite which is associated with anticholinergic side-effects, such as dry mouth and constipation

In Spain, Gebro has built a urology franchise where is currently commercializing Ialuril® for interstitial cystitis and bladder pain syndrome and Vejicur® for the treatment of bladder cancer. With this agreement with Recordati, Gebro Pharma Spain reinforces its urology portfolio.

Sergi Aulinas, CEO at Gebro Pharma Spain expressed "We are very pleased with this agreement because Kentera® offers a new alternative for patients with urinary incontinence that will significantly improve their quality of life. Furthermore, it represents an economic-efficient solution for the sustainability of the public system".

Overactive bladder in Spain

Overactive bladder (OAB) is a disorder of the bladder-storage function that encompasses frequency, urgency, and urge incontinence, singly or in combination. Symptoms of an overactive bladder occur because the muscles of the bladder are starting to contract involuntarily.

The prevalence of OAB in Spain is around 11,9% of the adult population, 10,8% in males and 12,8% in females. People older than 40 years are more likely to be affected and prevalence increases significantly, being the 24,5% of the adult population; 17,4% in males and 25,6% in females.

About Gebro Pharma

Gebro Pharma operates in Austria, Spain, Switzerland and Hungary with a total turnover of 152 Million EUR with a growth rate of 9% in 2013 and 475 employees. Headquarters are located in Fieberbrunn (Austria), together with a manufacturing site and R&D laboratories. The main therapeutic focus of the Group is pain and inflammation with a strong franchise in Rheumatology.

In Spain, Gebro started activities in 2002 and it is among the fastest growing companies within the market. Turnover in 2013 was over 43,4M EUR (+4%)

For further information: www.gebro.es

About Recordati

Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of around 4,000, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in the main European countries, in Russia, in other Central and Eastern European countries, in Turkey, in the United States of America and in North Africa. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. Consolidated revenue for 2012 was € 828.3 million, operating income was € 167.0 million and net income was € 118.5 million.

For further information: www.recordati.com

For further information:
Grupo Inforpress
Laura Puig
93 419 06 30
lpuig@inforpress.es

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES